

**Question for written answer E-004694/2025
to the Commission**
Rule 144
Ignazio Roberto Marino (Verts/ALE)

Subject: Irregularities in breast cancer screening programmes in Spain

The serious irregularities found in the management of breast cancer screening programmes in Spain undermine the principle that health is a fundamental right.

It has emerged in recent months that, in Andalusia and other regions in Spain, data on screening invitations, participation and diagnostic outcomes for the population have not been fully recorded or reported. This raises concerns vis-a-vis Council Recommendation of 9 December 2022, which calls on Member States to ensure that at least 90 % of the eligible population receive an invitation for screening by 2025.

At the same time, Spain has acquired mammography equipment using EU funds, including La Gomera (EUR 182 413, of which EUR 155 051 came from the European Regional Development Fund (ERDF) budget for 2014-2020) and Yecla (Murcia), listed as ‘eligible’ for REACT-EU funding. What is more, under the national AMAT-I plan, Spain has bought 61 mammography machines worth in excess of EUR 15.5 million. As no comprehensive national inventory exists, it is impossible to verify potential EU co-financing and actual screening activity.

In the light of the above:

1. Does the Commission plan to carry out a specific audit of ERDF/REACT-EU mammography equipment operations?
2. Does it consider it necessary to ask Spain to publish harmonised screening data on a regular basis, in an open format?
3. Will it clarify whether the EU-funded investments and AMAT-I purchases are in keeping with the requirement to provide a transparent and verifiable screening programme?

Submitted: 26.11.2025